Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Thyas Co. Ltd. is active in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This prosecution involves 1 distinct examiner and 1 distinct art unit, reflecting a focused approach where the company's current patent interests are being reviewed by a single administrative unit. Such a profile suggests that the company's current activity is limited to a single technical inquiry. Practitioners can observe that the 1 distinct art unit involved provides a centralized location for all current legal review.
The busiest examiner for the portfolio is SPENCE, JENNIFER SUZANNE, who is assigned 1 busiest examiner pending office action. This figure is identical to the total of 1 pending office action for the company, indicating that this examiner handles all active matters. With only 1 distinct examiner involved, the prosecution process is highly centralized. Practitioners can see that the 1 busiest examiner pending office action represents the full scope of the company's current interactions with the patent office, simplifying the management of the active portfolio to a single point of contact.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SPENCE, JENNIFER SUZANNE | 1 | 66.9% | +46.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17924480 | METHOD FOR PRODUCING REGENERATED T CELLS VIA IPS CELLS | SPENCE, JENNIFER SUZANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17924480 | METHOD FOR PRODUCING REGENERATED T CELLS VIA IPS CELLS | SPENCE, JENNIFER SUZANNE | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17924480 | METHOD FOR PRODUCING REGENERATED T CELLS VIA IPS CELLS | SPENCE, JENNIFER SUZANNE | 1633 | §103§112 | Non-Final OA | — | Pending | Nov 10, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThyas Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jennifer Suzanne Spence has the most, with 1 of Thyas Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
